CRBP Jul 2024 50.000 put
| Previous Close | 4.7000 |
| Open | 4.7000 |
| Bid | 5.1000 |
| Ask | 8.5000 |
| Strike | 50.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 4.7000 - 5.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 126 |
GlobeNewswireSYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/KgNo dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7)Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolvedEarly PK data demon
- GlobeNewswire
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL. 45th Annual Goldman Sachs Global Healthcare Conference Format: Presentation and one-on-one investor mee
- GlobeNewswire
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjuga
